Published in final edited form as:

Pharmacol Biochem Behav. 2011 November ; 100(1): 8–16. doi:10.1016/j.pbb.2011.07.013.

Regional mRNA expression of the endogenous opioid and dopaminergic systems in brains of C57BL/6J and 129P3/J mice: Strain and heroin effects

S.D. Schlussman, J. Cassin, Y. Zhang, O. Levran, A. Ho, and M.J. Kreek

The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York NY, USA

Abstract

We have previously shown strain and dose differences in heroin-induced behavior, reward and regional expression of somatostatin receptor mRNAs in C57BL/6J and 129P3/J mice. Using Real Time PCR we examined the effects of five doses of heroin on the levels of the transcripts of endogenous opioid peptides and their receptors and dopaminergic receptors in the mesocorticolimbic and nigrostriatal pathways in these same mice. Compared to C57BL/6J animals, 129P3/J mice had higher mRNA levels of *Oprk1* in the nucleus accumbens and of *Oprd1* in the nucleus accumbens and a region containing both the substantia nigra and ventral tegmental area (SN/VTA). In the cortex of 129P3/J mice, lower levels of both *Oprk1* and *Oprd1* mRNAs were observed. *Pdyn* mRNA was also lower in the caudate putamen of 129P3/J mice. Strain differences were not found in the levels of *Oprm1*, *Penk* or *Pomc* mRNAs in any region examined. Within strains, complex patterns of heroin dose-dependent changes in the levels of *Oprm1*, *Oprk1* and *Oprd1* mRNAs were observed in the SN/VTA. Additionally, *Oprd1* mRNA was dose-dependently elevated in the hypothalamus. Also in the hypothalamus, we found higher levels of *Drd1a* mRNA in C57BL/6J mice than in 129P3/J animals and higher levels of DAT (*Slc6a3*) mRNA in the caudate putamen of C57BL/6J animals than in 129P3/J counterparts. Heroin had dose-related effects on *Drd1a* mRNA in the hypothalamus and on *Drd2* mRNA in the caudate putamen.

Keywords

Endogenous opioid system; Dopaminergic system; Heroin; mRNA

1: Introduction

The endogenous opioid system consists of the mu, kappa and delta opioid receptors and their ligands (β -endorphin, dynorphins and enkephalins respectively). The endogenous opioid system is widely dispersed throughout the CNS and the periphery (e.g. (Boublik *et al.* 1983; DePaoli *et al.* 1994; Dumont & Lemaire 1984; Jamensky & Gianoulakis 1997; Konturek 1980; Mansour *et al.* 1994; Mansour *et al.* 1988; Minami *et al.* 1993; Pert *et al.* 1975;

© 2011 Elsevier Inc. All rights reserved.

Corresponding Author: S.D. Schlussman, Ph.D., The Rockefeller University, 1230 York Ave, New York, NY 10065, Phone: 212 327-8248, Fax: 212 327-8574, schluss@rockefeller.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Sanchez-Blazquez & Garzon 1985; Sharif & Hughes 1989)). In the CNS, opioid receptors and their ligands are found throughout the mesocorticolimbic and nigrostriatal dopaminergic systems, although the relative levels of each receptor and ligand show significant regional specificity (for review see e.g. (Mansour *et al.* 1988).

The mesocorticolimbic and nigrostriatal dopaminergic projections originate from cell bodies in the ventral tegmental area and the substantia nigra respectively, and project throughout the limbic system and to the striatum. A third dopaminergic system, the tuberoinfundibular system, originates from cell bodies in the hypothalamus and projects to the pituitary and the median eminence. Within these dopaminergic systems there are five distinct dopamine receptors (D1–5).

Dopamine receptors are known to colocalize with specific endogenous opioid peptides. The medium spiny neurons of the striatonigral projection contain the endogenous opioid peptide dynorphin and the dopamine D1 receptor, whereas those of the striatopallidal projection contain enkephalin and the dopamine D2 receptor (e.g. (Afifi 1994; Gerfen *et al.* 1990; Le Moine & Bloch 1995; McGinty 2007)).

Morphine, the biologically active metabolite of heroin (e.g. (Inturrisi *et al.* 1983; Selley *et al.* 2001)), binds to the mu opioid receptor on GABAergic interneurons in the substantia nigra and ventral tegmental area, which release GABAergic inhibition of dopamine release (e.g. (Johnson & North 1992)). This disinhibition results in elevated levels of dopamine in the projection fields (e.g. (Di Chiara & Imperato 1988a, b; Spanagel *et al.* 1990)) where it activates pre- and post-synaptic dopaminergic receptors.

In vivo, endogenous opioid peptides and their receptors modulate extracellular dopamine levels in nucleus accumbens and caudate putamen. Activation of the mu opioid receptor increases extracellular dopamine levels (Di Chiara & Imperato 1988a; Spanagel *et al.* 1990, 1992). Conversely, acute stimulation of *Oprk1* lowers dopamine levels (Di Chiara & Imperato 1988a; Spanagel *et al.* 1990, 1992; Zhang *et al.* 2003). Furthermore, administration of the selective *Oprk1* antagonist nor-BNI into the nucleus accumbens increased extracellular dopamine levels in the same region, demonstrating an ongoing inhibitory tone at the kappa opioid receptor (Spanagel *et al.* 1992). Consistent with this, we found that locally administered dynorphin A(1–17) decreased dopamine dialysate levels in the caudate putamen in mice, and blocked cocaine-induced conditioned place preference (Zhang *et al.* 2004a). This further implicates the kappa opioid receptor system in the dorsal striatum (i.e., caudate putamen) as an important mediator of the acquisition of reward-related behaviors of cocaine (Everitt & Robbins 2005; Fagergren *et al.* 2003; Porrino *et al.* 2004). Thus, the mu and kappa opioid peptides and ligands countermodulate dopaminergic tone.

Opiates affect mRNA levels within the striatum, including those of the endogenous opioid system (e.g. (Buzas *et al.* 1996; Garcia de Yebenes & Pelletier 1993; Georges *et al.* 1999; Romualdi *et al.* 1990, 1991; Trujillo *et al.* 1995; Yukhananov *et al.* 1993)) and the dopaminergic system (Spangler *et al.* 2003). In the nucleus accumbens and caudate putamen of rats, *Penk* mRNA levels were decreased by chronic administration of morphine (Basheer & Tempel 1993; Georges *et al.* 1999; Uhl *et al.* 1988). We have shown that acute intermittent morphine administration to rats produced elevations in *Pdyn* and *Oprm1* mRNA in the whole brain, with no effect on *Penk* mRNA levels (Wang *et al.* 1999). Acute morphine withdrawal increased *Penk* mRNA expression in the hypothalamus and striatum (Fukunaga *et al.* 1996; Gudehithlu & Bhargava 1995; Harbuz *et al.* 1991; Lightman & Young 1987).

There is a large body of data demonstrating considerable individual differences in the vulnerability to develop addictive disease. One way to study these individual, and perhaps

genetic, roots of vulnerability is to examine inbred strains of animals which are known to differ in their response to drugs of abuse (e.g. (Belknap *et al.* 1989; Kosten *et al.* 1994)). Numerous neurochemical and drug-induced behavioral differences have been described in C57BL/6J and DBA2 strains of mice (e.g. (Castellano *et al.* 1976; Crabbe *et al.* 1980; De Waele *et al.* 1992; Jamensky & Gianoulakis 1997; Phillips *et al.* 1994)). The C57BL/6 and 129 strains of mice are frequently used in the generation of knockout animals (e.g. (Crawley *et al.* 1997)); however these strains of mice have been studied much less extensively (for review see (Crawley *et al.* 1997)). Mice of various 129 sub-strains have consistently been shown to be less responsive to the locomotor stimulating effects of cocaine (e.g. (Kuzmin & Johansson 2000; Kuzmin *et al.* 2000; Miner 1997; Schlussman *et al.* 1998; Schlussman *et al.* 2003a) or rewarding effects of heroin (e.g. (Schlussman *et al.* 2008; Szumlinski *et al.* 2005)) or cocaine (Miner 1997). Szumlinski *et al.* showed that C57BL/6J mice developed conditioned place preference to heroin at a dose of 100 ug/kg, while 129/sVJ mice developed conditioned place aversion to the same dose (Szumlinski *et al.* 2005). We have shown significant differences in the development of heroin-induced conditioned place preference, in the same mice described in the study presented here, with C57BL/6J mice developing preference to relatively low doses of heroin and 129P3/J mice developing preference only to higher doses of heroin ((Schlussman *et al.* 2008). We suggested that this might represent a decreased sensitivity to the rewarding effects of heroin in 129P3/J mice relative to C57BL/6J animals.

Here we extend our behavioral studies by examining the relative expression of mRNAs of the endogenous opioid and dopaminergic systems in the same mice we found to differ in their behavioral response to heroin.

2: Materials and Methods

A total of 125 age-matched male mice (6 weeks old on arrival; Jackson Laboratory, Bar Harbor, ME), 55 C57BL/6J and 70 129P3/J, were studied. All animals were individually housed in an environmentally controlled room dedicated to this study. Food and water were available *ad lib* and animals were allowed two weeks to acclimate prior to the start of the experiments. Mice of each strain were randomly assigned to one of six groups, each administered a specific dose (0, 1.25, 2.5, 5, 10 or 20 mg/kg) of heroin (diacetyl-morphine HCl, obtained from NIH – NIDA). This study was approved by the Rockefeller University Institutional Animal Care and Use Committee and included provisions to minimize pain and discomfort.

Mice whose tissue was studied here were from a study of heroin-induced conditioned place preference which has been reported elsewhere (Schlussman *et al.* 2008). Animals in the 0 mg/kg group received i.p. injections of isotonic saline on all days of the study. Animals in the other groups received i.p. injections of heroin or saline on alternate days for a total of 8 days (for details see (Schlussman *et al.* 2008). Animals were sacrificed immediately following the testing session (24.5 hours following the last conditioning session) by decapitation following brief CO₂ exposure (< 20 seconds), their brains rapidly removed, and slices were cut with a rodent brain matrix (ASI Instruments, Warren, MI). The hypothalamus, cortex (an area containing the cingulate cortex area 1, the primary and secondary motor cortices and the prelimbic cortex (Franklin & Paxinos 1997)), nucleus accumbens, the caudate putamen and a region containing both the substantia nigra and the ventral tegmental area (SN/VTA) were dissected and homogenized in guanidium thiocyanate as previously described (Branch *et al.* 1992). RNA was isolated from homogenates of the hypothalamus, cortex and caudate putamen with the RNeasy system (Ambion [ABI], Austin TX) according to manufacturer's instructions. RNA from the nucleus accumbens and SN/VTA was isolated using an acid phenolic extraction (Chomczynski & Sacchi 1987). Following

RNA isolation, all samples were treated with DNase (Turbo DNA-free™, Ambion [ABI], Austin, TX). The quantity and quality of RNA in each extract was determined with the Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA).

cDNA was synthesized from each sample using the Super Script™ III first strand synthesis kit (Invitrogen, Carlsbad, CA). Five hundred ng of RNA from the hypothalamus, cortex and caudate putamen was used for reverse transcription. The entire nucleus accumbens and SN/VTA were utilized for generation of cDNAs. cDNAs were diluted 1:10 for real time PCR analysis.

Real time PCR analysis of the relative mRNA expression levels of *Oprm1*, *Oprk1*, *Oprd1*, *Penk*, proopiomelanocortin (*Pomc*; hypothalamus, caudate putamen only), *Pdyn*, tyrosine hydroxylase (*Th*; hypothalamus and SN/VTA only), DAT (*Slc6a3*; caudate putamen, nucleus accumbens and cortex) dopamine D1 receptor (*Drd1a*; hypothalamus, nucleus accumbens and caudate putamen), dopamine D2 receptor (*Drd2*; hypothalamus, nucleus accumbens and caudate putamen) and dopamine D3 receptor (*Drd3*; nucleus accumbens and caudate putamen) was conducted using commercially available primers and master mix (RT²qPCR™ primer assays and RT² Real Time™ SYBR® Green PCR Master Mix; Qiagen, Valencia, CA) according to manufacturer's directions in an ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA). Water controls for each primer set were included in every assay. Any sample with a cycle threshold (Ct) greater than that of the water control or a Ct greater than or equal to 35 was not included in the analysis. All data were normalized to *Gapdh* and reported as $2^{-\Delta Ct}$ where ΔCt is the cycle threshold of the mRNA of interest minus the cycle threshold of *Gapdh*.

Data for each mRNA of interest was analyzed by two-way ANOVA, Strain X Dose, followed by Newman-Keuls *post hoc* analysis where appropriate. Due to missing data points in certain C57BL/6J mice, resulting in an incomplete ANOVA design, significant main effects of Strain, in the cortex and nucleus accumbens were also analyzed in the saline treated animals only, using two-tailed t or Mann-Whitney U tests as appropriate. Any sample that was ≥ 2.5 standard deviations from the strain mean was considered an outlier and dropped from the analysis.

3: Results

We only present data which reached or neared statistical significance. All our findings are shown in supplemental Figures 1–11.

3.1 Endogenous Opioid Strain Effects

We observed significant region-specific strain differences in the mRNA levels of several components of the endogenous opioid system.

3.1.1 SN/VTA—In the region containing the substantia nigra and ventral tegmental area, the relative levels of *Oprd1* mRNA were significantly higher in 129P3/J mice compared to C57BL/6J counterparts ($F_{(1,87)} = 7.32$, $p < 0.01$; Fig. 1A).

3.1.2 Caudate putamen—In the caudate putamen, 129P3/J mice had lower levels of *Pdyn* mRNA than did C57BL/6J mice ($F_{(1,109)} = 7.67$, $p < 0.01$; Fig. 1B).

3.1.3 Nucleus accumbens—Several strain differences in the relative mRNA expression levels were observed in the nucleus accumbens.

Levels of *Oprm1* mRNA were greater in the nucleus accumbens of 129P3/J mice, relative to C57BL/6J mice, although this just missed statistical significance ($F_{(1,58)} = 3.96$, $p = 0.051$). However, when *Oprm1* mRNA levels in saline controls were compared, this effect was significant ($U = 1.00$, $P < 0.005$; Figure 1C).

There were apparently higher levels of *Oprm1* mRNA in the nucleus accumbens of 129P3/J mice compared to C57BL/6J animals, however, this did not reach statistical significance ($F_{(1,57)} = 2.87$, $p = 0.096$; Fig. 1D). Such a trend was also observed in saline controls ($t = 1.74$, $p = 0.096$).

In the nucleus accumbens, *Oprd1* mRNA levels were significantly higher in 129P3/J mice than in C57BL/6J animals ($F_{(1,38)} = 4.61$, $p < 0.05$; Fig. 1E). This significant difference was also observed between saline controls ($U = 6.00$, $p < 0.05$).

A significant main effect of Strain on *Penk* mRNA levels was not observed, however there was a trend for higher levels of expression in 129P3/J mice when saline controls were examined ($t = 1.91$, $p = 0.072$; Fig. 1F).

3.1.4 Cortex and Hypothalamus—Strain differences in the relative levels of mRNA for any component of the endogenous system were not found in either region.

3.2 Dopaminergic System Strain Effects

We observed regional strain differences in the relative expression levels of mRNAs of the dopaminergic system.

3.2.1 SN/VTA—In the SN/VTA there was a trend toward higher levels of *Th* mRNA expression in C57BL/6J mice relative to 129P3/J animals ($F_{(1,99)} = 3.11$, $p = 0.08$; Fig. 2A).

3.2.2 Caudate putamen—In the caudate putamen there were lower levels of *Slc6a3* mRNA in 129P3/J mice but this difference just missed statistical significance ($F_{(1,106)} = 3.90$, $p = 0.051$; Fig. 2B).

3.2.3 Nucleus accumbens—In the nucleus accumbens of 129P3/J mice, we found a trend toward lower levels of *Slc6a3* mRNA compared to C57BL/6J mice, ($F_{(1,65)} = 3.07$, $p = 0.084$). In the saline controls, this difference was statistically significant ($U = 15.00$, $p < 0.05$; Fig. 2C).

3.2.4 Cortex—Strain differences in the relative levels of mRNA of the dopaminergic system were not found.

3.2.5 Hypothalamus—In the hypothalamus, 129P3/J mice had lower levels of *Drd1a* mRNA compared to C57BL/6J mice ($F_{(1,95)} = 5.49$, $p < 0.05$; Fig. 2D). In the hypothalamus, *Drd2* mRNA levels appeared higher in 129P3/J mice than in C57BL/6J mice, although this difference did not reach statistical significance ($F_{(1,79)} = 3.35$, $p = 0.071$; Fig 2E).

3.3 Endogenous Opioid System; Heroin Dose Effects

Within strains, heroin had a complex pattern of effects on expression of several mRNAs. Interestingly, most of these were observed in the SN/VTA.

3.3.1 SN/VTA—A significant heroin Dose effect was observed, in this region, on the relative expression levels of mRNAs for all three endogenous opioid receptor genes (*Oprm1*, $F_{(5,101)} = 5.31$, $p < 0.0005$; *Oprk1*, $F_{(5,97)} = 3.59$, $p < 0.01$; *Oprd1*, $F_{(5,87)} = 2.95$, $p < 0.05$).

Oprm1 mRNA levels were significantly reduced by heroin at doses of 5 and 10 mg/kg ($p < 0.05$; Fig. 3A). *Oprm1* mRNA levels were also lower following 20 mg/kg of heroin, although this did not reach significance ($p = 0.08$). Lower doses of heroin (1.25 and 2.5 mg/kg) had no effect on levels of *Oprm1* mRNA. *Oprk1* mRNA levels were significantly increased by 2.5 mg/kg of heroin ($p < 0.05$; Fig. 3B). *Oprk1* mRNA levels appeared to increase following 1.25 mg/kg, but this did not reach statistical significance ($p = 0.07$). The higher doses of heroin had no effect on *Oprk1* mRNA. *Oprd1* mRNA levels in the SN/VTA were significantly elevated by the lowest dose of heroin ($p < 0.05$; Fig. 3D). We also observed a Strain by Dose interaction in the level of *Oprd1* mRNA in the SN/VTA ($F_{(5,87)} = 3.44$, $p < 0.01$). Newman-Keuls *post hoc* tests showed that the effect of the 1.25 mg/kg dose on expression levels of *Oprd1* mRNA was due to an elevation of *Oprd1* mRNA levels only in 129P3/J mice (data not shown). A significant main effect of heroin Dose on *Penk* mRNA expression was found in the SN/VTA ($F_{(5,104)} = 3.25$, $p < 0.01$; Fig. 3D). Newman-Kuels *post hoc* tests indicated an apparent lower level of *Penk* expression following the 10 mg/kg dose of heroin ($p = 0.08$).

3.3.2 Hypothalamus—In the hypothalamus, we observed a significant main effect of heroin Dose on relative levels of *Oprd1* mRNA ($F_{(5,78)} = 6.27$, $p < 0.0001$; Fig. 3E). Newman-Kuels *post hoc* tests showed that *Oprd1* mRNA levels were significantly elevated by the 10 mg/kg dose ($p < 0.05$). A significant Strain by Dose interaction was also observed ($F_{(1,78)} = 2.62$, $p < 0.05$). Newman-Kuels *post hoc* tests indicated that the main effect of Dose was due to an elevation of *Oprd1* mRNA by 10 mg/kg of heroin in C57BL/6J mice, but not in 129P3/J animals (data not shown).

3.4 Dopaminergic System

Heroin Dose Effects: A significant effect of heroin Dose on mRNA levels of the dopaminergic system was found in the caudate putamen and the hypothalamus.

Caudate putamen—In the caudate putamen, there was a significant main effect of Dose on the relative levels of *Drd2* mRNA ($F_{(5,111)} = 4.07$, $p < 0.005$; Fig. 4A). Newman-Kuels *post hoc* tests showed that heroin significantly elevated *Drd2* mRNA levels at the 2.5 mg/kg dose.

Hypothalamus—We observed a significant main effect of heroin Dose on *Drd1a* mRNA ($F_{(5,95)} = 2.76$, $p < 0.051$; Fig. 4B). Newman-Kuels *post hoc* tests showed that heroin significantly elevated *Drd1a* mRNA levels at the 10 mg/kg dose.

Heroin dose effects on mRNAs of the dopaminergic system were not observed in any other region examined.

4: Discussion

We identified region-specific strain differences in the relative expression levels of mRNA for important components of the endogenous opioid and the dopaminergic systems. The C57BL/6J and 129 strains of mice are known to differ in their behavioral response to cocaine (e.g. (Miner 1997; Schlussman *et al.* 1998; Schlussman *et al.* 2003a; Szumlinski *et al.* 2005; Unterwald & Cuntapay 2000)) and to heroin (e.g. (Schlussman *et al.* 2008; Szumlinski *et al.* 2005)). C57BL/6J mice have been shown to be more sensitive to thermal stimulation than 129/J (now 129P3/J) mice but less sensitive to morphine-induced antinociception (Mogil & Wilson 1997). 129/J mice have also been reported to be relatively resistant to developing dependence to morphine (Kest *et al.* 2002). Strains of 129 mice are consistently hypo-responsive to the behaviorally stimulating effects of cocaine, showing little

or no horizontal activity in response to cocaine (e.g. (Kuzmin *et al.* 2000; Miner 1997; Schlussman *et al.* 1998; Schlussman *et al.* 2003a)). Additionally, 129Ola/Hsd mice failed to acquire cocaine self-administration while C57BL/6J and DBA mice did (Kuzmin & Johansson 2000). We have previously shown, in the same animals studied in the present report, that C57BL/6J and 129P3/J mice differ in the locomotor-stimulating effect of heroin and in the establishment of heroin-induced conditioned place preference (Schlussman *et al.* 2008). Contrary to findings with cocaine, 129P3/J mice had a robust, dose-dependent locomotor response to heroin. The 129P3/J mice also developed conditioned place preference to heroin, although only to relatively high doses, to which C57BL/6J mice did not form a preference (Schlussman *et al.* 2008). Another substrain of 129 mice, 129X1/sVJ developed conditioned place aversion to a lower dose of heroin than we used (Szumlinski *et al.* 2005). Interestingly, this same sub-strain of mice was shown to require both contextual and drug cues in order to express conditioned place preference to morphine and it was suggested that higher relative levels of anxiety in the 129 strain of mice may explain these differences (Dockstader & van der Kooy 2001). We have also reported that these same mice whose tissues were used in the present study show significant differences in the expression of specific somatostatin receptor mRNAs within discrete regions of the central nervous system (Schlussman *et al.* 2010b).

In the region containing the substantia nigra and ventral tegmental area, and in the nucleus accumbens, we observed significantly higher levels of *Oprd1* mRNA in 129P3/J mice, and in the nucleus accumbens we report a trend toward higher levels of *Penk* mRNA in 129P3/J mice. Delta opioid receptors have been implicated in mediating anxiety-like behaviors. For instance, mice with life-long deletion of *Oprd1* show increased levels of anxiety (Filliol *et al.* 2000). Interestingly, 129/J mice have been shown to exhibit lower levels of anxiety, as measured in the open field, when compared to C57BL/6J mice (Montkowski *et al.* 1997). This may be related to a higher relative expression of *Oprd1* mRNA. We have reported that in the mice whose tissue was studied here, 129P3/J animals have higher levels of somatostatin receptor-2 mRNA in the caudate putamen (Schlussman *et al.* 2010a). Somatostatin receptor-2 knockout mice have increased anxiety-like behavior (Viollet *et al.* 2000) which suggest that higher levels of Somatostatin receptor 2 mRNA might be associated with decreased levels of anxiety. However, although we did not examine *sstr-2* mRNA levels in brain regions other than the caudate putamen. However, another group has suggested that 129/SvJ mice have high levels of anxiety during acute opiate withdrawal, in a conditioned place preference paradigm (Dockstader & van der Kooy 2001).

In addition to *Oprd1* mRNA, we also observed significantly higher levels of *Oprm1* mRNA, and a trend to higher levels of *Oprk1* mRNA in the nucleus accumbens of 129P3/J mice compared to that of C57BL/6J animals. The nucleus accumbens is an integral part of the reward pathway and is a major target of the mesocorticolimbic dopaminergic projection. We also found a small but statistically significant negative correlation between *Oprk1* mRNA levels in the nucleus accumbens of 129P3/J, but not in C57BL/6J, mice. The mu and kappa opioid receptors are thought to act in a countermodulatory manner to mediate dopaminergic tone (e.g. (Zhang *et al.* 2004a, b; Zhang *et al.* 2009)). Therefore it is somewhat counterintuitive to find elevated levels of mRNA for both of these receptors in this important dopaminergic terminal field, although it must be remembered that mRNA levels may not directly reflect protein levels, and *Oprm1* and *Oprk1* densities have not yet been compared in these two strains. A recent study has shown that DBA/2J mice are more sensitive to the rewarding effects of heroin (as measured by conditioned place preference) than are C57BL/6J animals (Bailey *et al.* 2010). These authors did not report basal differences in MOP-r binding densities in the nucleus accumbens between these two strains but they did report that MOP-r density was decreased by chronic heroin administration in many brain regions of the C57BL/6J animals, including the nucleus accumbens shell, while

MOP-r density was not altered in any region of the DBA/2J brain (Bailey *et al.* 2010). Interestingly, significant strain differences in the DAMGO stimulated [³⁵S] GTPγ were reported with higher levels of binding in the nucleus accumbens (core and shell) of C57BL/6J mice than in DBA/2J animals (Bailey *et al.* 2010).

In the caudate putamen we found a significantly lower level of *Pdyn* mRNA in 129P3/J mice than in C57BL/6J counterparts. This was unexpected. In another study, using solution hybridization / RNase protection, we did not find a difference in *Pdyn* mRNA in the caudate putamen of the two strains (Schlussman *et al.* 2003b). Additionally, dynorphin peptide lowers dopaminergic tone through its action on the kappa opioid receptor (e.g. (Zhang *et al.* 2004a)) and we did not observe differences in the basal levels of dopamine in the caudate putamen of these two strains (Zhang *et al.* 2001). Dynorphin, and other kappa opioid receptor agonists block the formation of cocaine-induced conditioned place preference (e.g. (Zhang *et al.* 2004a, b, 2005)). However we have reported that these same 129P3/J mice develop conditioned place preference to heroin, but only at relatively high doses (Schlussman *et al.* 2008). Previous studies have shown differences in the rewarding effects of opiates in C57BL/6J and DBA/2J mice, with often contradictory results (e.g. see (Bailey *et al.* 2010; Cunningham *et al.* 1992; Orsini *et al.* 2005; Semenova *et al.* 1995). Similar to the DBA mice, another strain, SWR, has also been shown to be less sensitive to the rewarding effects of opiates than C57BL/6J animals (Solecki *et al.* 2009). A recent study reported lower levels of *Pyn* and *Penk* mRNA in the dorsolateral striatum of SWR/J relative to either C57BL/6J or DBA/2J animals (Gieryk *et al.* 2010). In the nucleus accumbens we showed a trend toward higher levels of *Penk* mRNA levels in 129P3/J mice than in C57BL/6J animals. While we found that 129P3/J mice only develop conditioned place preference to relatively high doses of heroin (Schlussman *et al.* 2008), in the present study we did not find a statistically significant effect of heroin dose on *Penk* mRNA levels in this region. In an earlier report, Gieryk *et al.* reported that C57BL/6J mice had higher levels of *Penk* mRNA and lower levels of *Pdyn* mRNA in the nucleus accumbens than did either DBA/2J or SWR/J mice (Gieryk *et al.* 2010). Interestingly, this groups had previously shown that C57BL/6J have a high sensitivity to morphine reward (as measured by conditioned place preference) while both DBA/2J and SWR/J mice showed lower levels of morphine reward (Solecki *et al.* 2009) which led them to suggest that sensitivity to morphine reward may be related to basal levels of nucleus accumbal *Penk* and *Pdyn* mRNA (Gieryk *et al.* 2010). In the present study, we did not observe differences in levels of either *Penk* or *Pdyn* mRNA in the nucleus accumbens, despite having shown strain differences in the sensitivity to heroin-induced conditioned place preference (Schlussman *et al.* 2008). In the absence of a direct comparison of C57BL/6J, DBA/2J, SWR/J and 129P3/J, it is difficult to interpret these data.

In the present study we found lower levels of mRNA for *Th*, the rate limiting biosynthetic enzyme for dopamine, in the region containing the substantia nigra and ventral tegmental area, which may suggest reduced dopamine biosynthesis. We also observed lower levels of mRNA for the dopamine transporter (*Slc6a3*) in both the caudate putamen and the nucleus accumbens of 129P3/J mice compared to C57BL/6J animals.. Interestingly, rats that are more susceptible to acquisition of psychostimulant self-administration show lower levels of DAT binding sites in these regions (e.g. (Flores *et al.* 1998)) which led us to expect lower DAT mRNA levels in striatal regions of C57BL/6J mice. We did not observe an effect of heroin on *Slc6a3* mRNA levels. A previous report demonstrated higher levels of DAT binding in the nucleus accumbens, caudate putamen and olfactory tubercle of DBA/2J mice, compared to C57BL/6J animals, following chronic heroin administration (Bailey *et al.* 2010). These authors suggested that strain differences in heroin-induced levels of DAT binding might be partially responsible for the strain differences in heroin-induced locomotor activity in the strains (Bailey *et al.* 2010). However, contrary to the findings with DBA/2J mice, we reported that both the 129P3/J and C57BL/6J mice utilized in the present study

showed a robust locomotor response to heroin (Schlussman *et al.* 2008). Nonetheless, it would be of interest to examine DAT binding and mRNA levels in C57BL/6J and 129P3/J mice following chronic administration of heroin.

In the hypothalamus, we reported opposite strain differences on levels of mRNA for the *Drd1a* and *Drd2*. 129P3/J mice had lower levels of *Drd1a* mRNA, and trended toward higher levels of *Drd2* mRNA in this region. Activation of the stress responsive hypothalamic-pituitary-adrenal axis is, at least partially, regulated by dopaminergic *Drd1a* and *Drd2* (e.g. (Borowsky & Kuhn 1992; Eaton *et al.* 1996)) and we have shown that *Drd2* exerts tonic inhibition on hypothalamic *Pomc* mRNA expression (Zhou *et al.* 2004). We have not yet examined HPA function, in depth, in these two strains of mice, but in the present report we did not find strain differences in hypothalamic *Pomc* mRNA levels.

We did not observe a strain difference on the expression level of mRNA for *Drd1a*, *Drd2* or *Drd3* in either the nucleus accumbens or the caudate putamen. These findings for *Drd1a* mRNA support our earlier finding that, within the entire nucleus accumbens or caudate putamen there was no difference in the dopamine D1 receptor binding density in these strains (Schlussman *et al.* 2003a). Inbred strains of rats which have been reported to be more susceptible to acquisition of psychostimulant self-administration have fewer *Drd2* binding sites in the caudate putamen or nucleus accumbens (e.g. (Hooks *et al.* 1994)) and lower levels of *Drd2* mRNA in the nucleus accumbens (e.g. (Dalley *et al.* 2007; Hooks *et al.* 1994)). Similarly, inbred strains of rats (e.g. F344 and Lewis) which are known to differ in their acquisition of drug self-administration (e.g. (Guitart *et al.* 1992; Kosten *et al.* 2007)) show differences in the density of *Drd2* and *Drd3*. Specifically, Lewis rats, which have a higher propensity to self administer drugs of abuse, had lower levels of *Drd2* binding in the nucleus accumbens and caudate putamen than did F344 rats. Lewis rats also have lower levels of dopamine D3 receptor binding in the nucleus accumbens (Flores *et al.* 1998). Based on our previous behavioral studies in these two strains of mice, we had hypothesized that C57BL/6J mice would have lower levels of *Drd2* and *Drd3* mRNA in the caudate putamen and nucleus accumbens than do 129P3/J mice.

In the region containing the substantia nigra and ventral tegmental area, heroin had a dose-dependent effect on the relative mRNA levels of all three endogenous opioid receptors. *Oprm1* mRNA was lowered by the three highest doses of heroin (5, 10 and 20 mg/kg). Heroin doses of 1.25 or 2.5 mg/kg did not alter *Oprm1* mRNA levels. In contrast, *Oprk1* mRNA levels were increased by the 1.25 and 2.5 mg/kg dose, while the higher doses had no effect. This may be reflective of the countermodulation of dopamine by *Oprm1* and *Oprk1*.

Few other heroin effects were observed in the present study. However, it must be noted that in the context of the original conditioned place preference study, these animals were sacrificed either 24 or 48 hours following the last of four single injections of heroin. It is likely that additional effects would be observed following longer exposure to heroin. Additionally, real time PCR, like all PCR techniques, is based on an exponential function and, as a result, can only detect relatively large changes in mRNA levels. It is likely that additional heroin-induced effects on the mRNAs examined in the present report would be uncovered using techniques such as *in situ* hybridization or solution hybridization / RNase protection. Also, while we did not analyze the efficiency of amplification, it is possible that some of the strain effects that we report here may be due to strain differences in the efficiency of amplification. However, since the direction of strain-related differences in relative mRNA levels was gene-specific, we consider this possibility remote.

In summary, this report describes significant strain differences in the relative expression levels of important components of the endogenous opioid and dopaminergic systems. The

previously-reported behavioral differences between these two strains may be due, in part, to these strain differences in the endogenous opioid and dopaminergic systems.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank Dr. Eduardo Butelman for helpful discussions. 3, 6 diacetyl-morphine HCl was generously provided by NIH-NIDA Division of Drug Supply and Analytical Services. This work was supported by grants from NIH-NIDA (DA05130), the Arcadia Charitable Trust and The Carson Family Charitable Trust to MJK.

References

- Afifi AK. Basal ganglia: functional anatomy and physiology. Part 1. *J Child Neurol.* 1994; 9:249–260. [PubMed: 7930403]
- Bailey A, Metaxas A, Al-Hasani R, Keyworth HL, Forster DM, Kitchen I. Mouse strain differences in locomotor, sensitisation and rewarding effect of heroin; association with alterations in MOP-r activation and dopamine transporter binding. *Eur J Neurosci.* 2010; 31:742–753. [PubMed: 20384817]
- Basheer R, Tempel A. Morphine-induced reciprocal alterations in G alpha s and opioid peptide mRNA levels in discrete brain regions. *J Neurosci Res.* 1993; 36:551–557. [PubMed: 7908338]
- Belknap JK, Noordewier B, Lame M. Genetic dissociation of multiple morphine effects among C57BL/6J, DBA/2J and C3H/HeJ inbred mouse strains. *Physiol Behav.* 1989; 46:69–74. [PubMed: 2813556]
- Borowsky B, Kuhn CM. D1 and D2 dopamine receptors stimulate hypothalamo-pituitary-adrenal activity in rats. *Neuropharmacology.* 1992; 31:671–678. [PubMed: 1328919]
- Boublik JH, Clements JA, Herington AC, Funder JW. Opiate binding sites in bovine adrenal medulla. *J Recept Res.* 1983; 3:463–479. [PubMed: 6315932]
- Branch AD, Unterwald EM, Lee SE, Kreek MJ. Quantitation of preproenkephalin mRNA levels in brain regions from male Fischer rats following chronic cocaine treatment using a recently developed solution hybridization assay. *Brain Res Mol Brain Res.* 1992; 14:231–238. [PubMed: 1279343]
- Buzas B, Rosenberger J, Cox BM. Mu and delta opioid receptor gene expression after chronic treatment with opioid agonist. *Neuroreport.* 1996; 7:1505–1508. [PubMed: 8856708]
- Castellano C, Filibeck L, Oliverio A. Effects of heroin, alone or in combination with other drugs, on the locomotor activity in two inbred strains of mice. *Psychopharmacology (Berl).* 1976; 49:29–31. [PubMed: 822445]
- Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem.* 1987; 162:156–159. [PubMed: 2440339]
- Crabbe JC, Janowsky JS, Young ER, Riger H. Strain-specific effects of ethanol on open field activity in inbred mice. *Subst Alcohol Actions Misuse.* 1980; 1:537–543. [PubMed: 7302795]
- Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N, Hitzemann RJ, Maxson SC, Miner LL, Silva AJ, Wehner JM, Wynshaw-Boris A, Paylor R. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. *Psychopharmacology (Berl).* 1997; 132:107–124. [PubMed: 9266608]
- Cunningham CL, Niehus DR, Malott DH, Prather LK. Genetic differences in the rewarding and activating effects of morphine and ethanol. *Psychopharmacology (Berl).* 1992; 107:385–393. [PubMed: 1352057]
- Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, Laane K, Pena Y, Murphy ER, Shah Y, Probst K, Abakumova I, Aigbirhio FI, Richards HK, Hong Y, Baron JC, Everitt BJ, Robbins TW. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. *Science.* 2007; 315:1267–1270. [PubMed: 17332411]

- De Waele JP, Papachristou DN, Gianoulakis C. The alcohol-preferring C57BL/6 mice present an enhanced sensitivity of the hypothalamic beta-endorphin system to ethanol than the alcohol-avoiding DBA/2 mice. *J Pharmacol Exp Ther*. 1992; 261:788–794. [PubMed: 1578384]
- DePaoli AM, Hurley KM, Yasada K, Reisine T, Bell G. Distribution of kappa opioid receptor mRNA in adult mouse brain: an in situ hybridization histochemistry study. *Mol Cell Neurosci*. 1994; 5:327–335. [PubMed: 7804602]
- Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. *Proc Natl Acad Sci U S A*. 1988a; 85:5274–5278. [PubMed: 2899326]
- Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. *J Pharmacol Exp Ther*. 1988b; 244:1067–1080. [PubMed: 2855239]
- Dockstader CL, van der Kooy D. Mouse strain differences in opiate reward learning are explained by differences in anxiety, not reward or learning. *J Neurosci*. 2001; 21:9077–9081. [PubMed: 11698618]
- Dumont M, Lemaire S. Opioid receptors in bovine adrenal medulla. *Can J Physiol Pharmacol*. 1984; 62:1284–1291. [PubMed: 6095979]
- Eaton MJ, Cheung S, Moore KE, Lookingland KJ. Dopamine receptor-mediated regulation of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. *Brain Res*. 1996; 738:60–66. [PubMed: 8949928]
- Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. *Nat Neurosci*. 2005; 8:1481–1489. [PubMed: 16251991]
- Fagergren P, Smith HR, Daunais JB, Nader MA, Porrino LJ, Hurd YL. Temporal upregulation of prodynorphin mRNA in the primate striatum after cocaine self-administration. *Eur J Neurosci*. 2003; 17:2212–2218. [PubMed: 12786988]
- Filliol D, Ghazizadeh S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gaveriaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. *Nat Genet*. 2000; 25:195–200. [PubMed: 10835636]
- Flores G, Wood GK, Barbeau D, Quirion R, Srivastava LK. Lewis and Fischer rats: a comparison of dopamine transporter and receptors levels. *Brain Res*. 1998; 814:34–40. [PubMed: 9838033]
- Franklin, KBJ.; Paxinos, G. The mouse brain in stereotaxic coordinates. Academic Press, Inc; New York: 1997.
- Fukunaga Y, Nishida S, Inoue N, Kishioka S, Yamamoto H. Increase of preproenkephalin mRNA in the caudal part of periaqueductal gray by morphine withdrawal in rats: a quantitative in situ hybridization study. *Brain Res Mol Brain Res*. 1996; 42:128–130. [PubMed: 8915589]
- Garcia de Yebenes E, Pelletier G. Opioid regulation of proopiomelanocortin (POMC) gene expression in the rat brain as studied by in situ hybridization. *Neuropeptides*. 1993; 25:91–94. [PubMed: 8413862]
- Georges F, Stinus L, Bloch B, Le Moine C. Chronic morphine exposure and spontaneous withdrawal are associated with modifications of dopamine receptor and neuropeptide gene expression in the rat striatum. *Eur J Neurosci*. 1999; 11:481–490. [PubMed: 10051749]
- Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, Sibley DR. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. *Science*. 1990; 250:1429–1432. [PubMed: 2147780]
- Gieryk A, Ziolkowska B, Solecki W, Kubik J, Przewlocki R. Forebrain PENK and PDYN gene expression levels in three inbred strains of mice and their relationship to genotype-dependent morphine reward sensitivity. *Psychopharmacology (Berl)*. 2010; 208:291–300. [PubMed: 19997907]
- Gudeithlu KP, Bhargava HN. Modulation of preproenkephalin mRNA levels in brain regions and spinal cord of rats treated chronically with morphine. *Peptides*. 1995; 16:415–419. [PubMed: 7651893]

- Guitart X, Beitner-Johnson D, Marby DW, Kosten TA, Nestler EJ. Fischer and Lewis rat strains differ in basal levels of neurofilament proteins and their regulation by chronic morphine in the mesolimbic dopamine system. *Synapse*. 1992; 12:242–253. [PubMed: 1362292]
- Harbuz M, Russell JA, Sumner BE, Kawata M, Lightman SL. Rapid changes in the content of proenkephalin A and corticotrophin releasing hormone mRNAs in the paraventricular nucleus during morphine withdrawal in urethane-anaesthetized rats. *Brain Res Mol Brain Res*. 1991; 9:285–291. [PubMed: 1645431]
- Hooks MS, Juncos JL, Justice JB Jr, Meiergerd SM, Povlock SL, Schenk JO, Kalivas PW. Individual locomotor response to novelty predicts selective alterations in D1 and D2 receptors and mRNAs. *J Neurosci*. 1994; 14:6144–6152. [PubMed: 7931568]
- Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, Simon EJ. Evidence from opiate binding studies that heroin acts through its metabolites. *Life Sci*. 1983; 33 (Suppl 1):773–776. [PubMed: 6319928]
- Jamensky NT, Gianoulakis C. Content of dynorphins and kappa-opioid receptors in distinct brain regions of C57BL/6 and DBA/2 mice. *Alcohol Clin Exp Res*. 1997; 21:1455–1464. [PubMed: 9394118]
- Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. *J Neurosci*. 1992; 12:483–488. [PubMed: 1346804]
- Kest B, Palmese CA, Hopkins E, Adler M, Juni A, Mogil JS. Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. *Neuroscience*. 2002; 115:463–469. [PubMed: 12421612]
- Konturek SJ. Opiates and the gastrointestinal tract. *Am J Gastroenterol*. 1980; 74:285–291. [PubMed: 6258423]
- Kosten TA, Miserendino MJ, Chi S, Nestler EJ. Fischer and Lewis rat strains show differential cocaine effects in conditioned place preference and behavioral sensitization but not in locomotor activity or conditioned taste aversion. *J Pharmacol Exp Ther*. 1994; 269:137–144. [PubMed: 8169817]
- Kosten TA, Zhang XY, Haile CN. Strain differences in maintenance of cocaine self-administration and their relationship to novelty activity responses. *Behav Neurosci*. 2007; 121:380–388. [PubMed: 17469928]
- Kuzmin A, Johansson B. Reinforcing and neurochemical effects of cocaine: differences among C57, DBA, and 129 mice. *Pharmacol Biochem Behav*. 2000; 65:399–406. [PubMed: 10683479]
- Kuzmin A, Johansson B, Fredholm BB, Ogren SO. Genetic evidence that cocaine and caffeine stimulate locomotion in mice via different mechanisms. *Life Sci*. 2000; 66:PL113–118. [PubMed: 10680584]
- Le Moine C, Bloch B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. *J Comp Neurol*. 1995; 355:418–426. [PubMed: 7636023]
- Lightman SL, Young WS 3rd. Changes in hypothalamic preproenkephalin A mRNA following stress and opiate withdrawal. *Nature*. 1987; 328:643–645. [PubMed: 3614366]
- Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNS opioid receptors. *Trends Neurosci*. 1988; 11:308–314. [PubMed: 2465635]
- Mansour A, Fox CA, Burke S, Meng F, Thompson RC, Akil H, Watson SJ. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. *J Comp Neurol*. 1994; 350:412–438. [PubMed: 7884049]
- McGinty JF. Co-localization of GABA with other neuroactive substances in the basal ganglia. *Prog Brain Res*. 2007; 160:273–284. [PubMed: 17499120]
- Minami M, Hosoi Y, Taya T, Katao Y, Maekawa K, Katsumata S, Yabuuchi K, Onogi T, Satoh M. In situ hybridization study of kappa-opioid receptor mRNA in the rat brain. *Neurosci Lett*. 1993; 162:161–164. [PubMed: 7907172]
- Miner LL. Cocaine reward and locomotor activity in C57BL/6J and 129/SvJ inbred mice and their F1 cross. *Pharmacol Biochem Behav*. 1997; 58:25–30. [PubMed: 9264065]
- Mogil JS, Wilson SG. Nociceptive and morphine antinociceptive sensitivity of 129 and C57BL/6 inbred mouse strains: implications for transgenic knock-out studies. *Eur J Pain*. 1997; 1:293–297. [PubMed: 15102394]

- Montkowski A, Poettig M, Mederer A, Holsboer F. Behavioural performance in three substrains of mouse strain 129. *Brain Res.* 1997; 762:12–18. [PubMed: 9262153]
- Orsini C, Bonito-Oliva A, Conversi D, Cabib S. Susceptibility to conditioned place preference induced by addictive drugs in mice of the C57BL/6 and DBA/2 inbred strains. *Psychopharmacology (Berl)*. 2005; 181:327–336. [PubMed: 15864555]
- Pert CB, Kuhar MJ, Snyder SH. Autoradiographic localization of the opiate receptor in rat brain. *Life Sci.* 1975; 16:1849–1853. [PubMed: 1152615]
- Phillips TJ, Dickinson S, Burkhart-Kasch S. Behavioral sensitization to drug stimulant effects in C57BL/6J and DBA/2J inbred mice. *Behav Neurosci.* 1994; 108:789–803. [PubMed: 7986372]
- Porrino LJ, Lyons D, Smith HR, Daunais JB, Nader MA. Cocaine self-administration produces a progressive involvement of limbic, association, and sensorimotor striatal domains. *J Neurosci.* 2004; 24:3554–3562. [PubMed: 15071103]
- Romualdi P, Lesa G, Ferri S. Morphine affects prodynorphin gene expression in some areas of rat brain. *Ann Ist Super Sanita.* 1990; 26:43–46. [PubMed: 2393216]
- Romualdi P, Lesa G, Ferri S. Chronic opiate agonists down-regulate prodynorphin gene expression in rat brain. *Brain Res.* 1991; 563:132–136. [PubMed: 1786525]
- Sanchez-Blazquez P, Garzon J. Opioid activity of pro-enkephalin-derived peptides in mouse vas deferens and guinea pig ileum. *Neurosci Lett.* 1985; 61:267–271. [PubMed: 3001596]
- Schlussman SD, Ho A, Zhou Y, Curtis AE, Kreek MJ. Effects of “binge” pattern cocaine on stereotypy and locomotor activity in C57BL/6J and 129/J mice. *Pharmacol Biochem Behav.* 1998; 60:593–599. [PubMed: 9632245]
- Schlussman SD, Zhang Y, Kane S, Stewart CL, Ho A, Kreek MJ. Locomotion, stereotypy, and dopamine D1 receptors after chronic “binge” cocaine in C57BL/6J and 129/J mice. *Pharmacol Biochem Behav.* 2003a; 75:123–131. [PubMed: 12759120]
- Schlussman SD, Zhang Y, Yuferov V, LaForge KS, Ho A, Kreek MJ. Acute ‘binge’ cocaine administration elevates dynorphin mRNA in the caudate putamen of C57BL/6J but not 129/J mice. *Brain Res.* 2003b; 974:249–253. [PubMed: 12742644]
- Schlussman SD, Zhang Y, Hsu NM, Allen JM, Ho A, Kreek MJ. Heroin-induced locomotor activity and conditioned place preference in C57BL/6J and 129P3/J mice. *Neurosci Lett.* 2008; 440:284–288. [PubMed: 18579303]
- Schlussman SD, Cassin J, Levran O, Zhang Y, Ho A, Kreek MJ. Relative expression of mRNA for the somatostatin receptors in the caudate putamen of C57BL/6J and 129P3/J mice: strain and heroin effects. *Brain Res.* 2010a; 1345:206–212. [PubMed: 20478275]
- Schlussman SD, Cassin J, Levran O, Zhang Y, Ho A, Kreek MJ. Relative expression of mRNA for the somatostatin receptors in the caudate putamen of C57BL/6J and 129P3/J mice: Strain and heroin effects. *Brain Res.* 2010b10.1016/j.brainres.2010.05.025
- Selley DE, Cao CC, Sexton T, Schwegel JA, Martin TJ, Childers SR. μ Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. *Biochem Pharmacol.* 2001; 62:447–455. [PubMed: 11448454]
- Semenova S, Kuzmin A, Zvartau E. Strain differences in the analgesic and reinforcing action of morphine in mice. *Pharmacol Biochem Behav.* 1995; 50:17–21. [PubMed: 7700949]
- Sharif NA, Hughes J. Discrete mapping of brain Mu and delta opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors. *Peptides.* 1989; 10:499–522. [PubMed: 2550910]
- Solecki W, Turek A, Kubik J, Przewlocki R. Motivational effects of opiates in conditioned place preference and aversion paradigm--a study in three inbred strains of mice. *Psychopharmacology (Berl)*. 2009; 207:245–255. [PubMed: 19787337]
- Spanagel R, Herz A, Shippenberg TS. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. *J Neurochem.* 1990; 55:1734–1740. [PubMed: 1976759]
- Spanagel R, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. *Proc Natl Acad Sci U S A.* 1992; 89:2046–2050. [PubMed: 1347943]

- Spangler R, Goddard NL, Avena NM, Hoebel BG, Leibowitz SF. Elevated D3 dopamine receptor mRNA in dopaminergic and dopaminoreceptive regions of the rat brain in response to morphine. *Brain Res Mol Brain Res*. 2003; 111:74–83. [PubMed: 12654507]
- Szumliński KK, Lominac KD, Frys KA, Middaugh LD. Genetic variation in heroin-induced changes in behaviour: effects of B6 strain dose on conditioned reward and locomotor sensitization in 129-B6 hybrid mice. *Genes Brain Behav*. 2005; 4:324–336. [PubMed: 16011579]
- Trujillo KA, Bronstein DM, Sanchez IO, Akil H. Effects of chronic opiate and opioid antagonist treatment on striatal opioid peptides. *Brain Res*. 1995; 698:69–78. [PubMed: 8581505]
- Uhl GR, Navia B, Douglas J. Differential expression of preproenkephalin and prodynorphin mRNAs in striatal neurons: high levels of preproenkephalin expression depend on cerebral cortical afferents. *J Neurosci*. 1988; 8:4755–4764. [PubMed: 2904494]
- Unterwald EM, Cuntapay M. Dopamine-opioid interactions in the rat striatum: a modulatory role for dopamine D1 receptors in delta opioid receptor-mediated signal transduction. *Neuropharmacology*. 2000; 39:372–381. [PubMed: 10698003]
- Viollet C, Vaillend C, Videau C, Bluet-Pajot MT, Ungerer A, L'Heritier A, Kopp C, Potier B, Billard J, Schaeffer J, Smith RG, Rohrer SP, Wilkinson H, Zheng H, Epelbaum J. Involvement of sst2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice. *Eur J Neurosci*. 2000; 12:3761–3770. [PubMed: 11029646]
- Wang XM, Zhou Y, Spangler R, Ho A, Han JS, Kreek MJ. Acute intermittent morphine increases prodynorphin and kappa opioid receptor mRNA levels in the rat brain. *Brain Res Mol Brain Res*. 1999; 66:184–187. [PubMed: 10095091]
- Yukhananov R, Zhai QZ, Persson S, Post C, Nyberg F. Chronic administration of morphine decreases level of dynorphin A in the rat nucleus accumbens. *Neuropharmacology*. 1993; 32:703–709. [PubMed: 8103196]
- Zhang Y, Schlussman SD, Ho A, Kreek MJ. Effect of acute binge cocaine on levels of extracellular dopamine in the caudate putamen and nucleus accumbens in male C57BL/6J and 129/J mice. *Brain Res*. 2001; 923:172–177. [PubMed: 11743985]
- Zhang Y, Schlussman SD, Ho A, Kreek MJ. Effect of chronic “binge cocaine” on basal levels and cocaine-induced increases of dopamine in the caudate putamen and nucleus accumbens of C57BL/6J and 129/J mice. *Synapse*. 2003; 50:191–199. [PubMed: 14515336]
- Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Effect of the endogenous kappa opioid agonist dynorphin A(1–17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. *Psychopharmacology (Berl)*. 2004a; 172:422–429. [PubMed: 14712335]
- Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. *Psychopharmacology (Berl)*. 2004b; 173:146–152. [PubMed: 14712342]
- Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. *Psychopharmacology (Berl)*. 2005; 179:551–558. [PubMed: 15682306]
- Zhang Y, Picetti R, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Behavioral and neurochemical changes induced by oxycodone differ between adolescent and adult mice. *Neuropsychopharmacology*. 2009; 34:912–922. [PubMed: 18784649]
- Zhou Y, Spangler R, Yuferov VP, Schlussmann SD, Ho A, Kreek MJ. Effects of selective D1- or D2-like dopamine receptor antagonists with acute “binge” pattern cocaine on corticotropin-releasing hormone and proopiomelanocortin mRNA levels in the hypothalamus. *Brain Res Mol Brain Res*. 2004; 130:61–67. [PubMed: 15519677]

Highlights

1. C57-129 mouse strain differences in mRNA expression in the brain were found.
2. Heroin has a region specific effect on the EOS and DAergic system.

Figure 1. Endogenous Opioid System; Strain Effects. Regionally-specific strain differences in the relative expression levels of mRNA for components of the endogenous opioid system were found. Solid bars represent statistically significant differences; stippled bars represent strain differences which did not reach the 0.05 level of statistical significance.

Figure 2.

Dopaminergic System; Strain Effects. Regionally-specific strain differences in the relative expression levels of mRNA for components of the dopaminergic systems were found. Solid bars represent statistically significant differences; stippled bars represent strain differences that did not reach the 0.05 level of statistical significance.

Figure 3.

Endogenous Opioid System. Dose Effects within strains, a statistically significant main effect of Heroin Dose on relative mRNA levels of components of the endogenous opioid system was found in several brain regions. * represents Newman-Kuels *post-hoc* test $p < 0.05$.

Figure 4. Dopaminergic System; Dose Effects. Within strains, a statistically significant main effect of Heroin Dose was found for the relative expression of *Drd2* mRNA in the caudate putamen and on *Drd1a* mRNA in the hypothalamus. * represents Newman-Kuels *post-hoc* test $p < 0.05$.